RYR2 and myocardial infarction: WXKL treatment significantly reduced the expression of CaMKII, p-CaMKII (Thr-286), and PLB but significantly increased the expression of RYR2, p-PLB (Thr-17), and FKBP12.6 in rats with myocardial infarction to improve cardiac function and inhibit myocardial remodelling.